<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01904851</url>
  </required_header>
  <id_info>
    <org_study_id>STU 052012-093</org_study_id>
    <nct_id>NCT01904851</nct_id>
  </id_info>
  <brief_title>Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes</brief_title>
  <acronym>XLPAD</acronym>
  <official_title>Multi-Center Registry Comparing Stent and Non-Stent Based Interventional Outcomes for Patients With Peripheral Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      XLPAD is an observational study designed to evaluate the effectiveness and use of stent and&#xD;
      non-stent based therapies among PAD patients. The study will create a registry that will&#xD;
      include entry of procedural and clinical follow-up information into an online data collection&#xD;
      software, REDCAP.Data available since Jan 1 2005 will be included in the registry, until&#xD;
      14,000 patients have been included. The primary objectives of this observational registry&#xD;
      study are to:&#xD;
&#xD;
        1. Compare stent and non-stent based outcomes defined as a composite of symptom driven&#xD;
           target vessel revascularization (TVR), unplanned surgical revascularization of the&#xD;
           target limb and need for target limb amputation through 12 months post-index procedure&#xD;
           (Primary efficacy endpoint)&#xD;
&#xD;
        2. Compare stent and non-stent based outcomes defined as a composite of causes such as:&#xD;
           death, myocardial infarction (MI), stroke, peri-procedural complications, target vessel&#xD;
           revascularization (TVR) and unplanned surgical revascularization/amputation of the&#xD;
           target limb through 12 months (Primary safety endpoint)&#xD;
&#xD;
        3. Compare stent and non-stent based change in walking distance, Rutherford category and/or&#xD;
           ankle- brachial index (ABI) at 12 months compared to baseline (Primary clinical&#xD;
           improvement endpoint)&#xD;
&#xD;
      Approximately 14,000patients will be enrolled at approximately 60 sites worldwide. Enrollment&#xD;
      in the observational study will be monitored in an effort to achieve at least 20% (and no&#xD;
      more than 80%) of the population receiving stents as the initial treatment strategy.&#xD;
      Follow-up visits by sites will be reported at 6 and 12 months after index procedure to&#xD;
      collect data on treatment patterns and effectiveness, and outcomes. The follow-up procedures&#xD;
      are not mandated by the registry protocol. Each site will be encouraged to enter follow-up&#xD;
      information derived from clinically indicated follow-up visits. All events post-index&#xD;
      procedure till the 7th month will be reported under the 6 month follow-up form and subsequent&#xD;
      follow-up till the 13th month post-procedure will be entered on the 12 month follow-up form.&#xD;
&#xD;
      Patient management and treatment decisions are at the discretion of the care team per routine&#xD;
      clinical practice. The procedural aspects (including selection of stent type or non-stent&#xD;
      based treatments) and follow-up are not mandated by the registry and will be up to the&#xD;
      discretion of the operator and/or based upon the practice dictated by the clinical care of&#xD;
      the patient. Therefore the study poses minimal risk to the patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing an endovascular intervention receiving either stents or percutaneous&#xD;
      transluminal angioplasty (PTA) to the superficial femoral, popliteal, peroneal, anterior&#xD;
      tibial, or posterior tibial arteries will be entered into this registry. Patients undergoing&#xD;
      treatment of the external or common iliac arteries are not admissible to the registry, unless&#xD;
      these arteries were treated in addition to one of the five aforementioned arteries. The&#xD;
      registry will collect data in the form of patient background information, procedural data,&#xD;
      and follow-up data from the patient's medical records. Data available since Jan 1 2005 will&#xD;
      be included in the registry, until 14,000 patients have been included. The data will be&#xD;
      entered into a software, REDCAP, that automatically provides data quality verification and&#xD;
      processing.&#xD;
&#xD;
      Specifically, the data fields collected by the registry will be:&#xD;
&#xD;
      I) Background Information&#xD;
&#xD;
        1. Site, attending operator, and month-year of procedure&#xD;
&#xD;
        2. Patient height, weight, age, race, and sex&#xD;
&#xD;
        3. Rutherford claudication category, left and right ankle brachial index, ambulatory&#xD;
           status, claudication free distance&#xD;
&#xD;
        4. Risk factors such as diabetes, hypertension, hyperlipidemia, and prior history of lower&#xD;
           extremity percutaneous intervention&#xD;
&#xD;
        5. Patient comorbidities such as coronary artery disease, congestive heart failure, prior&#xD;
           myocardial infarction, stroke, transient ischemic attack, chronic kidney disease, and&#xD;
           other.&#xD;
&#xD;
      II) Lesion Characteristics (enter data for up to five lesions)&#xD;
&#xD;
        1. Access site relative to target limb, sheath size, target limb (left or right)&#xD;
&#xD;
        2. Target vessel: superficial femoral artery, popliteal artery, peroneal artery, anterior&#xD;
           tibial artery, or posterior tibial artery&#xD;
&#xD;
        3. Which, if any, Iliac arteries were treated during procedure&#xD;
&#xD;
        4. Target lesion location (ostial, proximal, medial, distal), estimated vessel diameter,&#xD;
           estimated vessel length&#xD;
&#xD;
        5. Lesion characteristics (heavily calcified, diffuse, thrombus, chronic total occlusion&#xD;
           (CTO), in-stent restenosis, restenosis post balloon angioplasty, profunda femoris&#xD;
           disease)&#xD;
&#xD;
        6. Planned revascularization strategy: stent or non-stent based&#xD;
&#xD;
      IIa) CTO Characteristics (Only required for CTO lesions)&#xD;
&#xD;
        1. Type of proximal and distal stumps, sidebranches present, collateral filling of distal&#xD;
           vessel, tortuosity, prior attempt to cross CTO&#xD;
&#xD;
        2. Antegrade or retrograde crossing strategy, crossing technique, number of attempts&#xD;
&#xD;
        3. Crossing devices used, microcatheters used, sub-intimal re-entry devices used (if any),&#xD;
           embolic protection device used&#xD;
&#xD;
      III) Intervention Details&#xD;
&#xD;
        1. Atherectomy device used (Cutting Balloon, TurboHawk, SilverHawk, Rotablator, Laser)&#xD;
&#xD;
        2. Pre and post-dilation balloon information (type, length, width, average atmospheric&#xD;
           pressure, number of inflations)&#xD;
&#xD;
        3. Stent information (indication for stents, length, width, maximum pressure, overlapping&#xD;
           with previous stents)&#xD;
&#xD;
        4. Aspiration/Thrombectomy used, thrombolytic therapy used&#xD;
&#xD;
        5. Percent change in stenosis and TIMI flows (before and after)&#xD;
&#xD;
      IV) Outcomes&#xD;
&#xD;
        1. Technical success (&lt;30% residual stenosis), procedural success (&lt;30% residual stenosis&#xD;
           without complications), and case comments&#xD;
&#xD;
        2. Anti-coagulation used, medical therapy (plavix, aspirin, lipid lowering therapy,&#xD;
           angiotensin receptor blocker, beta blocker, cilostazol, trental, insulin, oral&#xD;
           hypoglycemics)&#xD;
&#xD;
        3. Duration of procedure, fluoroscopy (amount used, type, and time)&#xD;
&#xD;
        4. Any procedural complications&#xD;
&#xD;
      V) Follow-Up&#xD;
&#xD;
        1. Month and year of follow-up&#xD;
&#xD;
        2. Rutherford category, left and right ankle brachial index, claudication-free distance,&#xD;
           ambulatory status, change in claudication (improved, same, or worsened)&#xD;
&#xD;
        3. Duplex ultrasound performed&#xD;
&#xD;
        4. Adverse events experienced (death, myocardial infarction, stroke, stent thrombosis,&#xD;
           stent fracture, angiography, repeat endovascular intervention, surgical&#xD;
           revascularization, amputation in target or non-target limb)&#xD;
&#xD;
      Follow-up data is recorded from clinical visits six and twelve months after the procedure. If&#xD;
      the patient undergoes a repeat intervention on the target limb, a new record is created for&#xD;
      the procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2033</completion_date>
  <primary_completion_date type="Anticipated">January 2033</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Target Limb Revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Target Lesion or Vessel Revascularization or Surgical Revascularization/Amputation of Target Limb</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">14000</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Stent</arm_group_label>
    <description>The patient received one or more stents to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in AT LEAST one of the lesions treated during the course of the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Stent</arm_group_label>
    <description>The patient did not receive a stent to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in ANY of the lesions treated during the course of the procedure.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diagnosed peripheral arterial disease who underwent endovascular&#xD;
        intervention, and received either a stent or non-stent based treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Underwent Endovascular Intervention&#xD;
&#xD;
          -  Treated Superficial Femoral, Popliteal, Peroneal, Anterior Tibial, or Posterior Tibial&#xD;
             Arteries&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failed Revascularization Attempt&#xD;
&#xD;
          -  Surgical Bypass&#xD;
&#xD;
          -  Only Iliac Artery Treated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Subhash Banerjee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ishita Tejani, BDS,MS,MSPH</last_name>
    <phone>2148573048</phone>
    <email>ishita.tejani@utsouthwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Heart Institute</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Denver VAMC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Corbet</last_name>
    </contact>
    <investigator>
      <last_name>Ehrin Armstrong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Khusrow Niazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Ball Memorial Hospital</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mid West Cardiovascular Research Foundation</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas Shammas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Boston Healthcare System</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St. Louis University Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Carolina East Health System</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28560</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Jessup, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>38732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christopher Bajzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Health Science Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mazen Abu-Fadel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integris Heart Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>George Chrysanthakopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Healthcare Network</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jon George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellmont CVA Heart Institute</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christopher Metzger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seton Heart Institute/ UT Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah J Benedict</last_name>
      <phone>512-324-9999</phone>
      <phone_ext>18171</phone_ext>
      <email>sarah.benedict@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Peter Monteleone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiothoracic and Vascular Surgeons</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Christus Sphon Hospital Corpus Christi-Shoreline</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Srikanth Damaraju, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John F Eidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Texas Veteran Affairs Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Subhash Banerjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Subhash Banerjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>El Paso Cardiovascular Care</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79925</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>North Dallas Research Associates</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Muhammad Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Health Sciences Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anand Prasad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.xlpad.org</url>
    <description>XLPAD Registry Website</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 17, 2013</study_first_submitted>
  <study_first_submitted_qc>July 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2013</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Subhash Banerjee</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Peripheral Arterial Disease</keyword>
  <keyword>Stents</keyword>
  <keyword>Registry</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Endovascular Procedures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

